The effects of dietary and lifestyle interventions among pregnant women who are overweight or obese on longer-term maternal and early childhood outcomes: protocol for an individual participant data (IPD) meta-analysis by Dodd, Jodie M et al.
PROTOCOL Open Access
The effects of dietary and lifestyle
interventions among pregnant women who
are overweight or obese on longer-term
maternal and early childhood outcomes:
protocol for an individual participant data
(IPD) meta-analysis
Jodie M. Dodd1,2*, Rosalie M. Grivell1,2, Jennie Louise1, Andrea R. Deussen1, Lynne Giles3, Ben W. Mol1,
Christina Vinter4,5, Mette Tanvig4,6, Dorte Moller Jensen6, Annick Bogaerts7, Roland Devlieger8, Riitta Luoto9,
Fionnuala McAuliffe10, Kristina Renault11, Emma Carlsen11, Nina Geiker12, Lucilla Poston13, Annette Briley13,
Shakila Thangaratinam14,15, Ewelina Rogozinska14,15 and Julie A. Owens1
Abstract
Background: The aim of this individual participant data meta-analysis (IPDMA) is to evaluate the effects of dietary
and lifestyle interventions among pregnant women who are overweight or obese on later maternal and early
childhood outcomes at ages 3–5 years.
Methods/design: We will build on the established International Weight Management in Pregnancy (i-WIP) IPD
Collaborative Network, having identified researchers who have conducted randomised dietary and lifestyle interventions
among pregnant women who are overweight or obese, and where ongoing childhood follow-up of participants has
been or is being undertaken. The primary maternal outcome is a diagnosis of maternal metabolic syndrome. The primary
childhood outcome is BMI above 90%.
We have identified 7 relevant trials, involving 5425 women who were overweight or obese during pregnancy,
with approximately 3544 women and children with follow-up assessments available for inclusion in the meta-analysis.
Discussion: The proposed IPDMA provides an opportunity to evaluate the effect of dietary and lifestyle interventions
among pregnant women who are overweight or obese on later maternal and early childhood health outcomes,
including risk of obesity. This knowledge is essential to effectively translate research findings into clinical practice and
public health policy.
Systematic review registration: This IPD has been prospectively registered (PROSPERO), ID number CRD42016047165.
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Background
Globally, 1.46 billion adults [1], and 170 million children
under the age of 18 years [2], are estimated to be over-
weight or obese. Obesity is occurring at an increasingly
early age, affecting more than 43 million children aged
0–5 years world-wide [3], leading the World Health
Organization to describe childhood obesity as “one of
the most serious public health challenges of the 21st
century [4]”. With obesity occurring earlier in life, the
aggregate exposure and risk of deleterious health conse-
quences also increases [5].
A variety of factors have been identified as increasing
an individual’s risk of increased adiposity and obesity in
childhood. In particular, both high maternal BMI and
excessive gestational weight gain during pregnancy have
been consistently identified as significant independent
pre-natal factors [6–9]. Recognized postnatal factors oper-
ating in early infancy include feeding (exposure to breast
feeding, formula feeding, and introduction of solids), ac-
tivity (including sedentary behaviours), and sleep duration,
although the associations between parental and postnatal
factors are complex, and the extent to which they may be
modified by intrauterine events is unclear [10].
Maternal overweight and obesity represents a significant
health issue for women during pregnancy and childbirth,
with estimates suggesting that over 50% of women enter
pregnancy with a BMI in excess of 25 kg/m2 [11]. While
there are well-documented risks associated with obes-
ity during pregnancy for both the woman and her in-
fant [12, 13], there is an increasing recognition of the
association between maternal obesity and subsequent
obesity in her offspring, developing in early infancy
[14] and extending into later childhood [15–17]. Inde-
pendent of maternal obesity, high gestational weight
gain (GWG) is also associated with an increased risk
of pre-school obesity [17–19].
Excessive GWG is recognized as a significant risk fac-
tor for maternal postpartum weight retention and the
subsequent development of obesity [20–22], contribut-
ing to an increase in inter-pregnancy BMI, and an in-
creased risk of adverse outcomes in a subsequent
pregnancy [22–24]. Excessive GWG is also consistently
associated with a greatly increased risk of a woman sub-
sequently developing diabetes in later life [25, 26], when
compared with women whose weight gain was within
the IoM recommendations. A similar increase in risk of
cardiovascular disease in later life has also been reported
among women with excessive pregnancy weight gain
[27–30].
The major complications associated with obesity dur-
ing pregnancy and childbirth for women and their in-
fants are well defined, and a comprehensive systematic
review led by Thangaratinam and colleagues [31] has
identified numerous studies assessing dietary and lifestyle
interventions in pregnancy. However, the effect of these
pregnancy interventions on later maternal and early child-
hood health is yet to be evaluated. The International
Weight Management in Pregnancy (i-WIP) Collaborative
group is near completion of an individual participant data
meta-analysis (IPDMA), funded by the UK NIHR, evaluat-
ing the effect of dietary and lifestyle interventions during
pregnancy on short-term pregnancy and birth outcomes
[32]. We propose to extend this existing collaboration to
evaluate the effect of dietary and lifestyle interventions
among pregnant women who are overweight or obese on
later maternal and early childhood health outcomes, es-
tablishing the International Weight Management in Preg-
nancy Collaboration: 3-year follow-up (i-WIP-3).
While systematic review and traditional methods of
meta-analysis generate robust evidence regarding health-
care interventions [33], recent calls have advocated that
level-1 evidence be attributed to IPDMA [34, 35]. Des-
pite this, IPDMA remains under-utilised as a methodo-
logical tool, limiting the quality and robustness of
clinical care guidelines and their recommendations [35].
Use of IPDMA methodology greatly increases statistical
power to generate unequivocal pooled risk estimates and
to identify key maternal characteristics and critical com-
ponents of the intervention contributing to maternal
and childhood health. Combining and analyzing the ex-
tensive volume of randomised controlled trial (RCT)
data available world-wide avoids the expense, duplication
of effort, and inevitable time delays of undertaking fur-
ther very large-scale trial(s) with pre-specified longer-
term primary outcomes relating to maternal and child
cardio-metabolic health.
Aims
Using IPDMA, we will determine the effects of antenatal
dietary and lifestyle interventions in pregnancy for
women who are overweight or obese on longer-term
health outcomes for the women and their children at 3-
5 years of age; this will also be assessed in particular
groups at greater risk to inform potential targeting of
the intervention.
With the available raw participant level data, we will
address the effect of antenatal dietary and lifestyle inter-
ventions on longer-term health outcomes, overall, and
according to maternal subgroups. The primary subgroup
analysis is early pregnancy body mass index (BMI) cat-
egory (25.0–29.9 vs ≥30.0 kg/m2). Secondary subgroup
analyses will also be carried out on subgroups defined by
the following characteristics:
1) Ethnicity (Caucasian vs Asian vs African);
2) Socioeconomic status (high vs low social
disadvantage) at time of randomisation during
pregnancy;
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3) Parity (0 vs ≥1) at time of randomisation during
pregnancy; and
4) Gestational weight gain (as a continuous variable,
and according to adherence to the Institute of
Medicine (IoM) gestational weight gain
recommendations) [36].
Methods
Study design
We will conduct an IPDMA, utilising an approach that
follows existing guidelines and that complies with the
PRISMA-IPD statement and recent reporting guidelines
for IPD meta-analysis (Additional file 1) [37].
Inclusion criteria for the studies and search strategy
Individual patient data from RCTs in which women with
a singleton, live gestation between 10+0–20+0 weeks, and
of BMI ≥ 25.0 kg/m2 at the time of the first antenatal
visit, were randomised to receive a diet and/or lifestyle
intervention or continued standard antenatal care, and
in which longer-term maternal and child follow-up has
been undertaken. The current studies were identified by
a systematic literature search within the i-WIP collabor-
ation [32]. We will update our previously described lit-
erature search, without language restrictions, in order to
identify any new potential relevant trials with planned or
published follow-up at the commencement of the pro-
ject and 1 year prior to its completion to minimise the
potential to miss relevant trials [32].
To date, we have identified seven such randomised tri-
als, with collaborators providing in principal agreement
to access de-identified individual participant data for
women and their children. The characteristics of each
trial are presented in Table 1. We are aware of two stud-
ies currently recruiting to the primary pregnancy inter-
vention, with an intention to conduct longer-term
maternal and child follow-up [38, 39].
Types of participants
Women with a singleton, live gestation between
10+0–20+0 weeks and of BMI ≥ 25.0 kg/m2 at the time of
their first antenatal visit, and in which subsequent ma-
ternal and child follow-up has been planned or under-
taken at 3–5 years of age.
Types of interventions
Antenatal dietary and/or lifestyle interventions com-
pared with continued standard antenatal care.
Data collection and management
Each trial will contribute de-identified patient level data
for each participant randomised. This will be stored in a
secure, centralised database with access available only to
authorised members of the i-WIP-3 data management
group. The database will build on that currently used in
the i-WIP collaboration. Specifically, data already housed
has been coded for anonymity and relates to the women
randomised (date of birth, center identification); baseline
descriptive information (age, parity, ethnicity, BMI, smok-
ing status, socioeconomic status, expected date of confine-
ment); allocated treatment intervention; and pregnancy
and birth outcome variables.
All data provided from individual trials will be checked
to ensure internal consistency as well as consistency
with published reports and to assess missing data, using
published data, trial protocols, and data collection
sheets. Similarly, the randomisation process for each trial
will be checked, including the chronological randomisa-
tion sequence, stratification variables, and allocation as-
signment to consider the distribution of prognostic
factors across treatment groups. Where inconsistencies
are identified, they will be discussed with the individual in-
vestigators and will be resolved through consensus. In the
initial stages, each trial will be analysed separately, and the
output generated cross-checked against published data
and verified by the individual investigator before being in-
corporated into the combined database.
Variables available through the i-WIP collaboration
Trial level information has already been collected and
exists within the database. This includes the number of
women randomised; methods of random allocation;
stratification variables; methods of allocation conceal-
ment; blinding of outcome assessment; nature of the
intervention (including the content of the intervention,
and the number and format in which the sessions were
provided); nature of standard antenatal care provided.
Maternal participant level information has already
been collected and exists within the database. This in-
cludes a unique participant code to ensure anonymity;
maternal age; body mass index; parity; ethnicity; smok-
ing status; and socioeconomic status.
Maternal pregnancy and birth outcome variables oc-
curring after the time of randomisation have been col-
lected and exist within the database. This includes
pregnancy outcomes (including gestational diabetes, pre-
eclampsia, and hypertension, pre-term birth, gestational
weight gain); and birth outcomes (including induction of
labour, mode of birth, estimated blood loss). Maternal
dietary and physical activity reports are also available.
Neonatal participant level information has already
been collected and exists within the database. A unique
neonatal identification code will be linked to the mater-
nal identification code to ensure anonymity. Outcome
variables include gestational age at birth, birth weight,
small and large for gestational age, perinatal death,
shoulder dystocia, birth trauma, and admission to the
neonatal intensive care unit (NICU).
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Variables to be collected through the i-WIP-3 Collaboration
Extended maternal participant level information will be
collected and entered into an expanded database housing
the above information. Outcome variables will include
height, weight, BMI, skinfold thickness measurements,
calculated percentage body fat and fat-free mass, dietary
and physical activity patterns, blood pressure, quality of
life and emotional wellbeing, and general health (Table 2).
Childhood participant level information will be col-
lected and entered into an expanded database housing
the above information. A unique childhood identification
code will be linked to the neonatal and maternal identifi-
cation codes to ensure anonymity. Outcome variables will
include height, weight, BMI, skinfold thickness measure-
ments, calculated percentage body fat and fat-free mass,
dietary and physical activity patterns, blood pressure, neu-
rodevelopmental outcome domains, and general health
(Table 3).
Establishment of outcome measures
To determine primary and secondary maternal and child
outcomes, we conducted a Delphi survey. An initial list
of outcomes was incorporated into a previous Delphi
survey conducted by the i-WIP group, with a specific
focus on outcomes relevant to women and their children
[40]. We undertook a two-stage Delphi survey (February
Table 1 Characteristics of the identified randomised trials
Trial name LIMIT [55–57] UPBEAT [58] ROLO [59] LiP [60–63] Belgian
Flanders
[64]
NELLI [65] The TOP
study [66]
Investigators Dodd, Grivell,
Owens
Poston McAuliffe Vinter, Tanvig, Jensen Bogaerts,
Devlieger
Luoto Renault
Funding NHMRC (ID 519240
and 1043178)
NIHR HRB Ireland Trygfonden, Denmark Finnish Diabetes
Research Fund
Sygekassernes
Helsefond;
Broedrene
Hartmann Fondon
Inclusion
criteria
Overweight or
obese
Obese Women with
prior birth of
infant >4 kg
Obese Obese Women of all
BMI categories
Obese
Setting Adelaide, South
Australia
Multiple
centres, United
Kingdom
Dublin,
Ireland
Odense, Denmark Multiple centres,
Belgium
Pirkananaa
region,
Southwest
Finland
Copenhagen,
Denmark
Intervention
intensity
3 face-to-face
sessions (2 with
dietitian, 1 with RA);
3 telephone
contacts
8 weekly
sessions with
health trainer
Initial group
dietary
education
session, 2
follow-up
sessions with
dietitian
4 sessions with
dietitian; weekly
physiotherapy sessions
4 sessions
with midwife
5 counselling
sessions with
midwife
Up to 13 sessions
(alternate face-to-
face and telephone
with dietitian)
Intervention
content
Healthy eating in
pregnancy; food
substitutions;
promote increased
physical activity;
identify barriers/
enablers
Healthy eating;
food
substitutions;
promote
increased
physical activity;
SMART goals
Healthy
eating in
pregnancy;
low glycaemic
index foods
Dietary advice
consistent with
national guidelines;
individual energy
requirements
calculated; moderate
physical activity
Dietary advice
consistent
with national
guidelines
Promote
increased
physical activity;
dietary advice
consistent with
national
guidelines
Mediterranean style
diet consistent with
national
recommendations;
increased physical
activity measured
by pedometer
Baseline
data
10–20 weeks
gestation
15–19 weeks
gestation
Prior to
18 weeks
gestation
10–14 weeks
gestation
Prior to 15
weeks gestation
8–12 weeks
gestation
Prior to 16 weeks
gestation
Primary trial
findings
Reduction infant
birth weight >4 kg
Improved diet and
physical activity
Reduction GWG
0.5 kg
Improved diet
and physical
activity
Reduction
GWG 1.3 kg
Improved
diet, physical
activity and
insulin
resistance
Reduction GWG 1.6 kg
Improved insulin
resistance
Reduction GWG
1.1 kg
Reduction
infant birth
weight >4 kg
Improved diet
and physical
activity
Reduction GWG
1.38 kg
Sample size 2212 women
randomised
1556 women
randomised
429 women
randomised
360 women
randomised
205 women
randomised
238 women
randomised
425 women
randomised
Follow-up 6, 18, and
36 months
6 and
36 months
6 and
60 months
6 and 36 months 36 months 36 months 6, 9, 18, and
36 months
Retention 72% (~1592) 60% (~930) 68% (~290) 54% (~194) 65% (~134) 65% (~154) 65% (~250)
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Table 2 Available maternal health outcomes
Trial name LIMIT [55–57] UPBEAT
[58]
ROLO [59] LiP [60–63] Belgian Flanders
[64]
NELLI [65] The TOP study
[66]
Investigators Dodd, Grivell, Owens Poston McAuliffe Vinter, Tanvig,
Jensen
Bogaerts,
Devlieger
Luoto Renault
Timing assessment 3 years 3 years 5 years 4–7 years 5–7 years 3 years
Height ✓ ✓ ✓ ✓ ✓ ✓ ✓
Weight ✓ ✓ ✓ ✓ ✓ ✓ ✓
Weight change ✓ ✓ ✓ ✓ ✓ ✓ ✓
BMI ✓ ✓ ✓ ✓ ✓ ✓ ✓
Circumferences
-Neck ✓
-Waist ✓ ✓
-Hip ✓
-Thigh ✓
-Mid upper arm ✓
-Wrist ✓
SFTM
-Subscapular ✓ ✓
-Triceps ✓ ✓
-Biceps ✓ ✓
-Suprailiac ✓ ✓
% Body fat ✓ ✓
DXA ✓ Subset
Bodpod ✓
BIA ✓ ✓
Dietary intake ✓ Also 6 months,
18 months
✓ ✓ ✓
Physical activity ✓ Also 6 months,
18 months
✓ ✓ ✓
Metabolic syndrome ✓ ✓ ✓
Glucose intolerance ✓ Subset ✓ ✓ ✓ At 12 months
postpartum
Insulin ✓
Type 2 DM ✓ Subset ✓ ✓ Self
report
✓ Fasting
glucose
✓
Hypertension/BP ✓ ✓ ✓ ✓ ✓ ✓
Hyperlipidaemia ✓ ✓ ✓
Inflammatory markers ✓ ✓
Transferrin??? ✓
DNA ✓ Saliva ✓
RNA ✓
Anxiety ✓ Also 6 months,
18 months
✓
Anxiety-eating ✓ TFEQ ✓
Depression ✓ Also 6 months,
18 months
✓ ✓ ✓
Quality of life ✓ Also 6 months, 18 months ✓ ✓ ✓
Health ✓ ✓ ✓ ✓
Reproductive health history ✓ ✓ ✓ ✓ ✓
Life events ✓ ✓
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Table 3 Available child outcomes
Trial name LIMIT [55–57] UPBEAT [58] ROLO [59] LiP [60–63] Belgian
Flanders [64]
NELLI [65] The TOP study [66]
Investigators Dodd, Grivell, Owens Poston McAuliffe Vinter, Tanvig,
Jensen
Bogaerts,
Devlieger
Luoto Renault
Timing
assessment
6 months, 18 months,
3 years
6 months,
3 years
6 months,
5 years
6 months,
3 years
6 months,
3 years
6 months,
3 years
6 months, 9 months,
18 months, 3 years
Height ✓ ✓ ✓ ✓ ✓ ✓ ✓
Weight ✓ ✓ ✓ ✓ ✓ ✓ ✓
BMI ✓ ✓ ✓ ✓ ✓ ✓ ✓
Head
circumference
✓ ✓ ✓ ✓
Neck circumference ✓ ✓
Arm
circumference
✓ ✓ ✓ ✓
Chest
circumference
✓ ✓
Abdominal
circumference
✓ ✓ ✓ ✓ ✓ ✓
Thigh
circumference
✓ ✓
Hip circumference ✓ ✓ ✓ ✓
Biceps SFTM ✓ ✓ ✓ ✓
Triceps SFTM ✓ ✓ ✓ ✓ ✓
Subscapular SFTM ✓ ✓ ✓ ✓
Suprailiac SFTM ✓ ✓
Abdominal SFTM ✓
Thigh SFTM ✓ ✓ ✓
Fat mass
(calculated)
✓ ✓ ✓ ✓ ✓ ✓
DEXA ✓ ✓ ✓
BOD-POD ✓ ✓
Blood pressure ✓ ✓ ✓ ✓ ✓
Cardiovascular
function
✓ ✓
Breast feeding ✓ ✓ ✓ ✓ ✓ ✓ ✓
Dietary patterns ✓ ✓ ✓ ✓ ✓
Physical activity ✓ ✓ ✓ ✓ ✓ ✓
Sedentary
behaviours
✓ ✓ ✓ ✓ ✓
Sleep time ✓ ✓ ✓ ✓
General health ✓ ✓ ✓ ✓ ✓ ✓
Ages and stages ✓ ✓ ✓ ✓ ✓
Cognitive
development
✓ ✓ ✓ ✓ ✓
Smoking
environment
✓ ✓ ✓ ✓ ✓ ✓
Blood specimen ✓ ✓ ✓ ✓
Salivary specimen ✓ ✓ ✓
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to April 2016) using a methodology consistent with
current recommendations [41], in order to prioritise ma-
ternal and childhood outcomes of relevance to clinical
practice. The panel involved members of the i-WIP col-
laborative steering committee, members from the
planned IPD investigators, and other identified multi-
disciplinary experts in the field.
An online survey tool was used and a link sent to indi-
vidual members of the panel, who were asked to score
each listed maternal and childhood outcome in terms of
clinical relevance for patient care. A nine-point Likert
scale was used to evaluate the importance, with a score
of 9 considered critical, while a score of 1 was consid-
ered of limited importance to patient care. In the first
round of the survey, participants were asked to suggest
other relevant outcomes that may not have been in-
cluded. These additional outcomes were included in the
second round of the survey. For each outcome, a median
and interquartile range (IQR) was calculated. This infor-
mation was then provided to panelists in the second
round of the survey. For each survey round, an e-mail
reminder was sent if no response had been received
within 2 weeks, with a second reminder sent after
4 weeks.
A total of 21 of 41 individuals completed both the first
and second rounds of the survey. The median and
IQR for maternal and childhood outcomes are shown
in Tables 4 and 5.
Primary outcome measures
The primary maternal outcome is a diagnosis of mater-
nal metabolic syndrome. The primary childhood out-
come is BMI above 90%. Secondary outcome measures
are presented in Tables 2 and 3.
Data management and statistical analyses
Data checking
The IPDMA project coordinator will check all new mater-
nal and child follow-up data provided from the individual
trials to ensure internal consistency and consistency with
published reports and to assess missing data, using pub-
lished data, trial protocols, and data collection sheets.
Similarly, the randomisation process for each trial will be
checked, including the chronological randomisation se-
quence, stratification variables, and allocation assignment
to consider the distribution of prognostic factors across
treatment groups. Where inconsistencies are identified,
they will be discussed with the individual investigators and
resolved through consensus. Initially, each trial will be
analysed separately, and the output generated will be
cross-checked against published data and verified by the
individual investigator before being incorporated into the
IPDMA database.
Data transformation
Data from each trial will be combined in a common data
set, after the above. Each patient will retain a unique
trial identifier. The combined data set will be used to de-
fine the new variables required to address the hypoth-
eses of the proposal.
Statistical analyses
A detailed statistical analysis plan will be prepared and
agreed upon by members of the i-WIP-3 collaboration,
prior to the conduct of any analyses. All randomised
participants with available outcome data will be included
in the analyses, on an intention-to-treat basis, according
to the treatment group to which the woman was allo-
cated at the time of randomisation (dietary and/or life-
style intervention vs standard care). Imputation methods
will be used to account for missing data.
The statistical analyses of this IPDMA will utilize
methods described in the Cochrane Collaboration Hand-
book [42] and as outlined for the i-WIP IPDMA [32].
Firstly, we will summarise the overall effect of each
intervention in relation to each outcome. Meta-analyses
of the effectiveness of antenatal interventions in preg-
nancy will be performed for the primary and secondary
maternal and child outcomes. We will include all patients
randomised and will adopt intention-to-treat principles.
All trials will be reanalysed separately, and the investi-
gators asked to confirm their individual results, with
resolution of any discrepancies. We will then perform a
one-step IPDMA to generate a pooled intervention ef-
fect. A two-step IPDMA will also be conducted as a sec-
ondary analysis for comparison with the one-step
results, unless convergence issues with the one-step ana-
lysis require the use of the two-step approach. A one-
step approach accounts for clustering of participants
within studies and analyses IPD from all trials simultan-
eously. A two-step approach first estimates the interven-
tion effect from the IPD in each study separately and
then pools them using a conventional meta-analysis
of the intervention effect estimates obtained. While
one and two-step meta-analyses typically yield similar
results, both will be undertaken to ensure robust con-
clusions [43, 44].
We anticipate that there will be evidence of heterogen-
eity in our IPDMA and will therefore use a random
effects approach to account for between study hetero-
geneity in intervention effect. Heterogeneity will be sum-
marised using the I-squared statistic (which describes
the proportion of total variability due to between study
heterogeneity) and the estimated between-study variance
(‘tau-squared’).
For continuous outcomes, we will use mean differ-
ences, which will be standardized where possible if out-
come scales differ substantially, with adjustment for
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baseline values using analysis of covariance [45]. For bin-
ary outcomes, we will calculate relative risks and incorp-
orate modelling where required (for example, logistic
regression to adjust for clustering). We will assume that
the random effects contributing to heterogeneity at the
individual trial level will be normally distributed, al-
though it is unlikely that violation of this assumption
will affect the results of the analysis [46].
The subgroups to be considered as causes of hetero-
geneity and potential modifiers of the effect of the inter-
vention include maternal BMI category, ethnicity,
socioeconomic status, parity, and maternal gestational
weight gain. We will generate summary intervention ef-
fects in each subgroup using the same random-effects
meta-analysis approach as described above. Subgroup
analyses, if not carefully planned, can lead to misleading
results, and we will therefore exercise caution in the in-
terpretation of subgroup results, with adjustment for
multiple testing.
To explore the possibility of chance effects contribut-
ing to the findings of our subgroup analyses, we will in-
corporate treatment-covariate interaction terms in the
analysis. This will ensure that we estimate the pooled
within-trial interaction of interest separately from the
across-trial (meta-regression) interaction, as recom-
mended because the former is the desired information
as it is based solely on patient-level information [47, 48].
A secondary analysis will evaluate the association be-
tween maternal gestational weight gain and maternal and
child outcomes in overweight and obese women. We will
fit a suitable regression model to account for clustering of
participants within individual trials and quantify how each
1-unit increase in weight gain changes the risk of each
outcome. As the relationship may be non-linear, we will
use fractional polynomial terms [49]. Modelling will use
linear regression for continuous variables and logistic re-
gression for binary variables, and will also account for
clustering of participants within trials, as well as their allo-
cated treatment intervention during pregnancy.
Study quality assessment and evaluation of nonresponse
bias
We will consider all recorded variables, even those not
reported in the published studies. The quality of each
trial will be assessed [50, 51] to evaluate the integrity of
the randomisation and follow-up procedure. We will
evaluate the risk of bias in individual studies by consid-
ering six items used in the Cochrane risk of bias tool: se-
quence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting,
and other potential sources of bias.
If individual patient data are not received from all
identified studies, the potential for bias due to nonre-
sponse will be assessed by descriptive comparison of
Table 4 Maternal outcomes determined from the Delphi survey
(first round median and IQR in brackets)
Maternal outcomes Median IQR
Maternal metabolic syndrome (8.00, 2.00) 8 1
Maternal glucose intolerance (8.00, 2.00) 8 1.25
Maternal type 2 diabetes (8.00, 2.00) 8 2
Maternal hypertension (8.00, 2.00) 7.5 1
Maternal physical activity patterns (6.00, 3.00) 7 1
Maternal weight change (7.00, 3.50) 7 1.25
Maternal hyperlipidaemia (6.00, 3.00) 6 2
Maternal dietary patterns (6.00, 3.50) 6 2
Maternal anxiety/depression (6.00, 2.00) 6 2
Maternal quality of life (6.00, 2.00) 6 1.25
Maternal body fat (%) (5.00, 2.00) 5 2
Maternal elevated CRP (4.00, 3.00) 4.5 2
Maternal skin fold thicknesses (5.00, 2.00) 4.5 2
Table 5 Childhood outcomes determined from the Delphi survey
(first round median and IQR in brackets)
Child outcomes Median IQR
BMI (7.00, 2.50) 7 2
BMI≥ 85% (7.00, 1.50) 7 1.25
BMI z score (7.00, 2.00) 7 1.25
Blood pressure-continuous (7.00, 2.00) 7 1.25
Hypertension (SBP and DBP) (7.00, 2.00) 7 1.25
Abdominal fat mass (7.00, 3.00) 7 1.25
Impaired cardiovascular function (8.00, 2.50) 7 2.25
Physical activity measures/patterns (7.00, 2.50) 7 2.25
Sedentary activity measures (7.00, 3.00) 7 2
Food frequency/eating–FFQ (7.00, 3.00) 7 1.25
Developmental milestones (7.00, 2.50) 7 2
General health (7.00, 1.50) 7 1
Insulin/glucose homeostasis (7.00, 2.50) 7 2
Cognitive development (new) 7 2.25
Lipid profile (7.00, 2.50) 6.5 1.25
Circumferences (6.00, 2.00) 6 1
Skinfold thicknesses (6.00, 1.00) 6 1
Calculated fat-free mass (%) (6.00, 1.50) 6 1.25
Calculated total fat mass (%) (6.00, 1.50) 6 1.25
Breastfeeding duration (6.00, 2.00) 6 1.25
Sleep patterns/duration (6.00, 2.00) 6 1
Leptin/adiponectin (6.00, 2.00) 6 1
Asthma/allergy (new) 6 1
Child behaviour (new) 6 2
Inflammatory markers (6.00, 2.00) 5 2
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participating and non-participating studies, in terms of
study characteristics (sample size, where and when con-
ducted, etc.), patient population, and main effect esti-
mate (where possible). Comparison of results from the
two-stage meta-analysis with those of the one-stage ana-
lysis will also be used to assess the potential for nonre-
sponse bias.
Sample size
There are a total of 3544 women and children with data
available at the 3-year follow-up across the 7 trials; the
smallest study has a sample size of 134. Power and
coverage (alpha/type I error) for the main child out-
come (BMI > 90%) and for the main subgroup analysis
(interaction between treatment and maternal early preg-
nancy BMI category) were investigated across 1000 simu-
lated datasets using the ipdpower command in Stata [52].
The simulated datasets incorporated study-specific fixed
intercepts (base log-odds), fixed effects for maternal BMI
category and treatment-by-BMI interaction, and random
effects for treatment.
For the main childhood outcome (BMI > 90%), assum-
ing a reduction in incidence from 21.0% in the control
group to 16.7% in the treatment group (corresponding to
a treatment effect OR of approximately 0.75), and stipulat-
ing a high degree of between-study heterogeneity for the
random treatment effect (SD on the log-odds scale corre-
sponding to 1/3 of the average effect), there was 85%
power (95% CI 82.6–87.2%) to detect the treatment effect.
Coverage was acceptable at 92% (95% CI 90.1–93.6).
For the main subgroup analysis, assuming that the
treatment effect in the higher BMI category is approxi-
mately 1.5 times that in the lower BMI category (OR of
1.5); that the control group OR for the higher BMI cat-
egory compared to the lower BMI category is approxi-
mately 1.6, and that about 70% of women have early
pregnancy BMI in the higher category (≥30.0), there is
greater than 80% power to detect the interaction effect
(82.2%, with 95% CI 79.6–84.5%), with good coverage of
96.4% (95% CI 95.0–97.5%).
Management considerations
The i-WIP-3 Collaboration will have a steering group
consisting of the current named authors, which includes
a representative from each of the individual randomised
trials contributing individual patient data, in addition to
the project coordinator and statistician. The steering
committee will meet initially to discuss and finalise the
definitions and outcomes to be assessed and the statis-
tical processes proposed. Where possible, one face-to-
face collaborator meeting will be scheduled each year, at
which key decisions, including the project design, analysis
plan, and interpretation of findings will be discussed.
The operational requirements of the project will be
performed by the project coordinator and statistician,
in conjunction with the individual trial managers and
statisticians and will be overseen by the chair of the
steering committee.
Publication considerations
Each member of the steering committee will be provided
with the results of the analysis, and a meeting will be
held to discuss and interpret the findings. The current
named authors will be responsible for the preparation of
manuscripts, which will then be circulated to each mem-
ber of the committee for further discussion prior to sub-
mission for publication. Where possible, each member of
the steering committee will be named as an author on any
publications arising from the analysis and on behalf of the
i-WIP-3 collaboration as a whole, with acknowledgement
of all participating collaborators within the manuscript.
Discussion
There is an increasing recognition of the association be-
tween maternal obesity, high infant birth weight, and the
subsequent development of childhood obesity. In a large
population cohort from the United States, the overall in-
cidence of infant birth weight above 4 kg was approxi-
mately 12% [53]. However, approximately 1 in 5 children
who were obese at ages 5–6 years had birth weight
above 4 kg, increasing to almost one third of obese indi-
viduals at age 14 years [53]. Therefore, antenatal inter-
ventions which are successful in reducing the risk of
maternal gestational weight and adiposity gain and/or
high birth weight infants represent a public health strat-
egy of considerable significance to tackle the global issue
of increasing obesity and adverse health in children and
in adults [54].
Our proposed IPDMA provides a unique opportunity
to evaluate the effect of dietary and lifestyle interven-
tions among pregnant women who are overweight or
obese on later maternal and early childhood health out-
comes, including risk of obesity. Importantly, we will
build on the successful existing i-WIP project, which has
standardized the baseline characteristics of women re-
cruited to randomised trials, interventions, and short-
term pregnancy and birth outcomes. While each of the
identified randomised trials are sufficiently similar in de-
sign and outcomes to allow meaningful meta-analysis to
occur, the intensity of the intervention provided and so-
cial demographics of included participants is diverse
with the IPD proposed enabling identification of effect
modifiers through pre-specified subgroup analyses.
Furthermore, this can be achieved in a relatively effi-
cient manner and with sufficient statistical power, avoid-
ing the expense, duplication of effort, and inevitable
time delays in undertaking another large-scale pregnancy
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intervention trial with a pre-specified primary outcome
of later maternal or early childhood obesity. This know-
ledge is essential to effectively translate research findings
into clinical practice and public health policy, and to
maximise the return on publicly funded research invest-
ments globally.
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